CD274 and liposarcoma: This single arm, open label trial tested the safety and efficacy of avelumab (anti-PD-L1 antibody) combined with trabectedin in patients with advanced leiomyosarcoma (18 patients with non-uterine and 6 with uterine disease) and liposarcoma (11 patients).